Eterna Therapeutics 株価情報 (NASDAQ: ERNA)

最新ニュース Eterna Therapeutics (NASDAQ:ERNA) 株価情報

Eterna Therapeutics

Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.

Eterna Therapeutics Inc

Earnings

News

Johnson Controls Building Solutions Backlog $13.20B +11% YoY

Vestas Wind Systems (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWDRY#OTC">VWDRY</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.16 by 31.25 percent. This is a 600 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $6.55 billion which beat the analyst consensus estimate of $5.75 billion by 13.91 percent. This is a 27.63 percent increase over sales of $5.13 billion the same period last year.

Earnings Beats

VWDRY

Vestas Wind Systems Q4 EPS $0.21 Beats $0.16 Estimate, Sales $6.55B Beat $5.75B Estimate

Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) reported quarterly sales of $12.00 billion which beat the analyst consensus estimate of $11.77 billion by 1.98 percent. This is a 20.77 percent increase over sales of $9.94 billion the same period last year.

UBER

Uber Technologies Q4 Sales $12.00B Beat $11.77B Estimate

He succeeds George R. Oliver following a thorough succession planning process.&nbsp;

Management

Johnson Controls Appoints Joakim Weidemanis As CEO Effective March 12, 2025;

As of Feb. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the<a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Orthofix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>)</h3>
<ul>
<li>Orthofix Medical announced that it will release its fourth quarter and full-year 2024 financial results on Tuesday, Feb. 25, 2025 before the opening bell. The company has a <a href="https://www.benzinga.com/quote/OFIX">52-week high of $20.73</a>.</li>
<li>RSI Value: 77.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>OFIX Price Action: Shares of Orthofix Medical gained 3.1% to close at $18.76 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Globus Medical Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>)</h3>
<ul>
<li>On Feb. 3, Interactive Brokers reported a year-over-year increase in daily average revenue trades for January. The company's stock gained around 10% over the past month and <a href="https://www.benzinga.com/quote/GMED">has a 52-week high</a> of $94.93.</li>
<li>RSI Value: 74</li>
<li>GMED Price Action: Shares of Globus Medical fell 0.4% to close at $92.18 on Tuesday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

GMED

OFIX

Top 2 Health Care Stocks That May Crash In February

Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.59 by 8.47 percent. This is a 39.13 percent increase over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $5.43 billion which beat the analyst consensus estimate of $5.29 billion by 2.50 percent. This is a 4.17 percent increase over sales of $5.21 billion the same period last year.

Johnson Controls Intl Q1 2025 Adj EPS $0.64 Beats $0.59 Estimate, Sales $5.43B Beat $5.29B Estimate

Timken Says It Is Implementing Cost Reduction Actions That Are Expected To Generate Gross Savings Of $75M In 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Peter Arment upgraded Mercury Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) from Neutral to Outperform and raised the price target from $37 to $58. Mercury shares closed at $42.09 on Tuesday. <a href="https://www.benzinga.com/quote/MRCY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Brian Tanquilut upgraded the rating for Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from Hold to Buy and raised the price target from $140 to $150. Cardinal Health shares closed at $125.17 on Tuesday. <a href="https://www.benzinga.com/quote/CAH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Kenneth Worthington upgraded Janus Henderson Group plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) from Neutral to Overweight and boosted the price target from $44 to $53. Janus Henderson shares closed at $44.02 on Tuesday. <a href="https://www.benzinga.com/quote/JHG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Christopher Danely upgraded the rating for NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) from Sell to Neutral and raised the price target from $200 to $210. NXP Semiconductors shares closed at $202.40 on Tuesday. <a href="https://www.benzinga.com/quote/NXPI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark analyst Cody Acree upgraded Silicon Laboratories Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) from Hold to Buy and maintained the price target of $160. Silicon Laboratories shares closed at $136.60 on Tuesday. <a href="https://www.benzinga.com/quote/SLAB/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NXPI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="612" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05065433/image-40-1024x612.png" alt="" class="wp-image-766905" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05065433/image-40-1024x612.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05065433/image-40-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05065433/image-40-768x459.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05065433/image-40.png 1082w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

Upgrades

Analyst Ratings

Janus Henderson Group plc Ordinary Shares

MRCY

NXPI

SLAB

This NXP Semiconductors Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday

Guidance

Harley-Davidson shares are trading lower following a Q4 earnings miss.

Timken Sees 2025 Adjusted EPS Of $5.30 - $5.80, Est $6.32; Revenue To Decline 4% To 1% In Total YoY, Including Unfavorable Foreign Currency Translation

Harley-Davidson Sees Full-Year HDMC Revenue Flat To Down 5%, Operating Income Margin 7.0%-8.0%, Sees Full-Year Diluted EPS Flat To Down 5%

Harley-Davidson Q4 HDMC Revenue $420.489M

Timken (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKR#NYSE">TKR</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $0.99 by 17.17 percent. This is a 15.33 percent decrease over earnings of $1.37 per share from the same period last year. The company reported quarterly sales of $1.07 billion which met the analyst consensus estimate. This is a 1.65 percent decrease over sales of $1.09 billion the same period last year.

Timken Q4 2024 Adj EPS $1.16 Beats $0.99 Estimate, Sales $1.073B Beats $1.067B Estimate

On Tuesday, February 4, U.S. markets closed higher, driven by energy sector gains, as optimism grew over a potential U.S.-China trade breakthrough. Trump delayed Mexico-Canada tariffs but imposed new levies on China, prompting retaliation. Strong corporate earnings lifted sentiment, with <a target="_blank" href="https://www.benzinga.com/news/earnings/earnings-beats/25/02/43468342/palantir-rockets-on-strong-q4-2024-was-only-a-dress-rehearsal-for-ai-growth-says-analyst" rel="noreferrer noopener">Palantir surging 24%.</a> Fed officials warned of inflation risks from tariffs, while job openings missed expectations.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/02/43485885/pharma-bro-martin-shkreli-defends-palantirs-valuation-amid-24-surge-says-ai-firms-cash-flow-justifies-expensive-price" rel="noreferrer noopener">&#8216;Pharma Bro&#8217; Martin Shkreli Defends Palantir&#8217;s Valuation Amid 24% Surge, Says AI Firm&#8217;s Cash Flow Justifies &#8216;Expensive&#8217; Price</a>.
In economic data, U.S. job openings fell by 556,000 to 7.6 million in December, missing estimates of 8.0 million. Factory orders dropped 0.9% to $578.5 billion, following a revised 0.8% decline in November.
Most S&amp;P 500 sectors ended higher, led by energy, tech, and communication services, while utilities and consumer staples declined.
The Dow Jones Industrial Average was up 0.30% and closed at 44,556.04, the S&amp;P 500 closed higher by 0.72% at 6,037.88, and the Nasdaq Composite rose 1.35% to finish at 19,654.02.
Aisa Markets Today
<ul>
<li>On Wednesday, Japan&#8217;s Nikkei 225 closed higher by 0.08% at 38,809.00, led by gains in the Textile, Marine Transport, and Services sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 gained 0.51% at 8,416.90, led by gains in the Gold, Metals &amp; Mining and Resources sectors.</li>
<li>India's Nifty 50 closed lower by 0.23% at 23,685.10, while Nifty 500 rose 0.22% closing at 21,776.00,</li>
<li>China&#8217;s Shanghai Composite fell 0.63% and closed at 3,229.49; Shanghai Shenzhen CSI 300 was down 0.56% at 3,795.08.</li>
<li>Hong Kong&#8217;s Hang Seng closed the session lower by 0.93% at 20,597.09.</li>
<li>Chinese markets fell as U.S.-China trade tensions escalated, with Shanghai and Hong Kong indexes declining. China announced retaliatory tariffs on U.S. goods, effective February 10, 2025.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 was down 0.22%.</li>
<li>Germany&#8217;s DAX fell 0.24%.</li>
<li>France&#8217;s CAC declined 0.25%.</li>
<li>U.K.&#8217;s FTSE index 100 traded lower by 0.01%.</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 0.85% at $72.05/bbl, and Brent was down 0.88% at $75.53/bbl.</li>
<li>Oil prices declined as rising U.S. stockpiles and escalating trade tensions with China fueled economic growth concerns, countering Trump&#8217;s efforts to restrict Iranian crude exports.</li>
<li>Natural Gas declined 1.35% to $3.210.</li>
<li>Gold was trading higher by 0.55% at $2,891.46, Silver was down 0.16% to $32.965, and Copper rose 0.32% to $4.3680.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures were down 0.20%, S&amp;P 500 futures declined 0.56% and Nasdaq 100 futures slid 0.95%.
Forex at 05:30 AM ET
<ul>
<li>The U.S. dollar index declined 0.54% to 107.42, the USD/JPY fell 1.11% to 152.64, and the USD/AUD fell 0.49% to 1.5907.</li>
<li>The yuan weakened as U.S.-China trade tensions hit markets, while the yen surged on expectations of Bank of Japan rate hikes. The dollar fell against major currencies, with traders watching China&#8217;s response to tariffs and potential U.S. negotiations. Japan&#8217;s strong wage data fueled further yen gains.</li>
</ul>
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Mixed, Europe Slips As China's Tariff Retaliation Hits Sentiment - Global Markets Today While US Slept

Canaccord Genuity analyst Maria Ripps maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and raises the price target from $650 to $700.

Price Target

SPOT

Canaccord Genuity Maintains Buy on Spotify Technology, Raises Price Target to $700

META REVERSES EARLY WEAKNESS AT TIME OF ALERT 
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="728" height="639" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/04212646/Screen-Shot-2025-02-04-at-4.18.30-PM.png" alt="" class="wp-image-5470" style="width:728px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/04212646/Screen-Shot-2025-02-04-at-4.18.30-PM.png 728w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/04212646/Screen-Shot-2025-02-04-at-4.18.30-PM-300x263.png 300w" sizes="(max-width: 728px) 100vw, 728px" /></figure>
Meta Platforms, Inc. (META) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:10 AM on February 4th, a significant trading signal occurred for Meta Platforms, Inc. (META) as it demonstrated a Power Inflow at a price of $696.21. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Meta&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Meta&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for META, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $696.21. The returns on the High price ($707.71) and Close price ($704.18) after the Power Inflow were respectively 1.7% and 1.2%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case the high of the day and close were very close but that is not always the case
Past Performance is Not Indicative of Future Results

Equities

Technicals

TRADEPULSE POWER INFLOW ALERT: META PLATFORMS INC.,META, MOVES UP OVER 1.5 % AFTER ALERT FROM TRADEPULSE.

Earnings Misses

Harley-Davidson Q4 2024 GAAP EPS $(0.93) Misses $(0.67) Estimate

WIIM

CPRI

Capri Holdings shares are trading lower after the company reported worse-than-expected Q3 financial results and FY25, FY26 outlook.

Canaccord Genuity analyst Richard Close maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Hold and lowers the price target from $21 to $19.

PINC

Canaccord Genuity Maintains Hold on Premier, Lowers Price Target to $19

Vestas Wind Systems (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWDRY#OTC">VWDRY</a>) announced its Q4 earnings on Wednesday, February 5, 2025 at 03:00 AM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Vestas Wind Systems beat estimated earnings by 31.0%, reporting an EPS of $0.21 versus an estimate of $0.16.
Revenue was up $1.42 billion from the same period last year.
<h3>Analysis of Past Earnings</h3>
In the previous quarter, the company missed on EPS by $0.03, resulting in a 14.000000000000002% drop change in the share price the following day.

To track all earnings releases for Vestas Wind Systems <a href="https://www.benzinga.com/quote/VWDRY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Vestas Wind Systems Earnings Analysis: Q4 Recap

Eterna (ERNA) Therapeutics has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock ...

Eterna regains compliance with Nasdaq

Eterna Therapeutics announces up to $1 million stock repurchase program

Eterna (ERNA) Therapeutics announced that its Board of Directors has authorized a stock repurchase program of up to $1M of the company's outstandin...

Eterna announces up to $1M stock repurchase program

Eterna (ERNA) Therapeutics announced it will investigate the ability of its lead iMSC-based cell therapy, ERNA-101, to induce and modulate antitumo...

Eterna launches research to evaluate ERNA-101

Eterna Therapeutics ( ($ERNA) ) has provided an update. Eterna Therapeutics Inc. has faced a compliance issue with the Nasdaq Stock Market due to i...

Eterna Therapeutics Faces Nasdaq Compliance and Board Changes

Eterna (ERNA) Therapeutics announced positive results from a preclinical study on the company's lead cell therapy product, ERNA-101, which is desig...

Eterna announces preclinical study results on ERNA-101

Firefly Neuroscience, Eterna Therapeutics, and Nature's Miracle Holding are the 3&nbsp;Penny Stocks&nbsp;to watch on January 16, 2025, based on&nbs...

3 Penny Stocks to Watch Now, 1/16/25

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Eterna (ERNA) Therapeutics announced the addition of Jerome Zeldis, M.D., Ph.D., and Blythe Sather, Ph.D., to the company's scientific advisory boa...

Eterna appoints Zeldis, Sather to scientific advisory board

AIFF

ANIX

AZTR

BDTX

ERNA

EVAX

GBIO

GTBP

IBIO

KAPA

KROS

LEXX

NMHI

OSTX

PHIO

RGNX

SLRX

SLXN

SNGX

TNFA

Health Care

Press Releases

General

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Comments

Eterna Therapeutics

ニュース

最新ニュース Eterna Therapeutics (NASDAQ:ERNA) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル